Prognostic factors for patients with relapsed central nervous system nongerminomatous germ cell tumors.
Mohammad H Abu ArjaDiana S OsorioÁlvaro Lassaleta-AtienzaRichard T GrahamScott L CovenJoseph R StanekEric BouffetJonathan L FinlayMohamed S AbdelbakiPublished in: Pediatric blood & cancer (2021)
We aimed toidentify prognostic factors that may help better understand the behavior of relapsed central nervous system nongerminomatous germ cell tumors. We identified nine studies, including 101 patients; 33 patients (33%) were alive 12 months post-initial relapse. Sixty percent of patients with serum/cerebrospinal fluid (CSF) alpha-fetoprotein (AFP) level ≤25 ng/mL at initial diagnosis were survivors compared with 28% among patients with serum/CSF AFP level >25 ng/mL (P = 0.01). Seventy-one percent of patients who achieved complete response/continued complete response (CR/CCR) by the end of therapy at relapse were survivors compared with 7% among patients who had less than CR/CCR (P < 0.0001). Forty-eight percent of patients who received marrow-ablative chemotherapy followed by autologous hematopoietic cell rescue (HDCx/AuHCR) following relapse were survivors compared with 12% among patients who did not receive HDCx/AuHCR (P = 0.0001). Local relapse site, gross total surgical resection, and radiotherapy at relapse were not associated with improved outcomes.
Keyphrases
- prognostic factors
- cerebrospinal fluid
- germ cell
- end stage renal disease
- free survival
- young adults
- ejection fraction
- chronic kidney disease
- newly diagnosed
- acute myeloid leukemia
- bone marrow
- dendritic cells
- squamous cell carcinoma
- diffuse large b cell lymphoma
- peritoneal dialysis
- type diabetes
- early stage
- radiation therapy
- hodgkin lymphoma
- metabolic syndrome
- multiple myeloma
- mesenchymal stem cells
- immune response
- locally advanced
- insulin resistance
- children with cerebral palsy